Paper Details

  1. Home
  2. Paper Details

Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial.

Author: , AgaAnna-Birgitte, BackJohan, BaklandGunnstein, Bay LaurbjergTrine, BrodinEli, BøyesenPernille, FaustiniFrancesca, GiovanniCagnotto, GjertssonInger, GlinatsiDaniel, GrenholmEmma, GrondalGerdur, GudbjornssonBjorn, HaavardsholmEspen A, HeibergMarte Schrumpf, HendricksOliver, HetlandMerete Lund, Hørslev-PetersenKim, JustSøren Andreas, KapetanovicMeliha Crnkic, KastbomAlf, KrabbeSimon, LampaJon, LarssonPer, LendKristina, LindegaardHanne, LindqvistJoakim, LjosåMaud Kristine, LorenzenTove, NordströmDan C, NurmohamedMichael T, OlsenInge Christoffer, ParmannePinja, RannioTuomas, RizkMilad, RudinAnna, SokkaTuulikki, StevensDavid J, SöderberghAnnika, UhligTill, UhrenholtLine, VedderDaisy, van VollenhovenRonald F, ØrnbjergLykke Midtbøll, ØstergaardMikkel

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Abatacept and certolizumab pegol were more effective than active conventional therapy in achieving clinical remission in patients with early rheumatoid arthritis.
Paper Details　
Original Abstract of the Article :
BACKGROUND: The optimal first-line treatment in early rheumatoid arthritis (RA) is debated. We compared clinical and radiographic outcomes of active conventional therapy with each of three biological treatments with different modes of action. METHODS: Investigator-initiated, randomised, blinded-ass...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1136/ard-2023-224116

データ提供：米国国立医学図書館（NLM）

Early Rheumatoid Arthritis: A Race Against Time

Rheumatoid arthritis (RA) is a chronic inflammatory disease that can cause significant joint damage if left untreated. This research explores the effectiveness of different treatment strategies in early RA, comparing the outcomes of active conventional therapy with three biological treatments. The study aims to provide insights into the optimal first-line treatment for patients with early RA.

The researchers conducted a randomized controlled trial involving 812 patients with early RA. They compared the efficacy of active conventional therapy with three biological treatments: abatacept, certolizumab pegol, and tocilizumab. The study found that both abatacept and certolizumab pegol were more effective than active conventional therapy in achieving remission, while tocilizumab showed a similar, but less statistically significant, effect.

The Race Against Time: Finding the Right Path for Early RA

The study highlights the importance of early intervention in RA, as delaying treatment can increase the risk of long-term joint damage.

Navigating the Desert of Rheumatoid Arthritis: Finding the Right Oasis

This research provides valuable insights into the optimal treatment strategies for early RA, emphasizing the importance of individualized care based on patient needs and risk factors.

Dr.Camel's Conclusion

Early rheumatoid arthritis, like a looming sandstorm in the desert, demands swift action. This research provides valuable guidance on navigating the desert of RA, highlighting the effectiveness of different treatment approaches and urging early intervention for optimal outcomes.

Date :
  1. Date Completed 2023-09-21
  2. Date Revised 2023-10-12
Further Info :

Pubmed ID

37423647

DOI: Digital Object Identifier

10.1136/ard-2023-224116

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.